SCHEMBL4396834

SCHEMBL4396834

[CH2]S(=O)(=O)c1ccc(C)cc1C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
POLB P06746 1/20 0.47
ALOX12 P18054 1/20 0.47
GFER P55789 1/20 0.47
KMT2A Q03164 1/20 0.46
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 1/20 0.45
MEP1B Q16820 1/20 0.45
RAPGEF4 Q8WZA2 3/20 0.44
KDM4E B2RXH2 1/20 0.44
F2 P00734 1/20 0.44
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7896750 0.81 ALDH1A1 (0.50) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL2236507 0.81 ALDH1A1 (0.50) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL4396839 0.79 L3MBTL1 (0.63) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL330673 0.79 ALDH1A1 (0.49) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL11587901 0.78 MEP1B (0.46) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL7803001 0.78 TSHR (0.47) KMT2ALMNAMEP1BPKMMAPK1
SCHEMBL30266645 0.77 PDIA6 (0.55) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL11587898 0.77 ALDH1A1 (0.47) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL6113219 0.77 ALDH1A1 (0.47) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL28417626 0.77 ALDH1A1 (0.47) ALDH1A1MAPTHPGDPOLBALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306376-A1 OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME MITSUI CHEMICALS, INC. (JP) 2009-12-10 US disclosed
US-7405030-B2 Imide compound and optical recording media made by using the same MITSUI CHEMICALS, INC. (JP) 2008-07-29 US disclosed
EP-1930339-A2 Imide compound MITSUI CHEMICALS, INC. (JP) 2008-06-11 EP disclosed
US-20070259151-A1 Imide compound and optical recording media made by using the same MITSUI CHEMICALS, INC. (JP) 2007-11-08 US disclosed
US-7259260-B2 Imide compound and optical recording media made by using the same MITSUI CHEMICALS, INC. (JP) 2007-08-21 US disclosed
US-20070054084-A1 Optical recording medium and compound used for the same MITSUI CHEMICALS, INC. (JP) 2007-03-08 US disclosed
EP-1672626-A1 OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM Mitsui Chemicals, Inc. (JP) 2006-06-21 EP disclosed
US-20050208425-A1 Imide compound and optical recording media made by using the same YAMAMOTO CHEMICALS, INC. (JP) 2005-09-22 US disclosed
EP-1445115-A1 IMIDE COMPOUNDS AND OPTICAL RECORDING MEDIA MADE BY USING THE SAME Mitsui Chemicals, Inc. (JP) 2004-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306376-A1 OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME CACNA1B, KCNN4, KCNN2 ALDH1A1 4231/4885MAPT 415/4885HPGD 2788/4885
US-20050208425-A1 Imide compound and optical recording media made by using the same CRY1, MTNR1A, TRPA1 ALDH1A1 1336/4885MAPT 2420/4885HPGD 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.